Treatment-resistant anxiety disorders
The DOI matches its Crossref record; 86 of the 88 references it cites were found in a registry or an index.
Abstract
Several epidemiological studies confirmed that Anxiety Disorders as a group are the most prevalent psychiatric conditions in the United States. The importance of these conditions is underlined by the fact that they cause significant disability, poor quality of life, alcohol and drug abuse. Anxiety disorders are treatable conditions and respond to the front-line interventions such as serotonin reuptake inhibitors and cognitive behavioral therapy. However, only about 60% of patients respond to those treatments to any significant degree. Many still have residual symptoms or stay treatment refractory. The group of anxiety patients that is resistant to the treatment has been shown to have very poor quality of life and have highest rate of suicidal attempts than any other disorders. Many biological, treatment specific and social factors are affecting treatment resistance. In this paper, we are attempting to review reasons for the treatment resistance. In addition, we would like to review current strategies that could be helpful in reducing treatment resistance and aiding people chronically suffering from these severe and disabling conditions.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, comorbid anxiety and depression is associated with more severe somatic symptoms, poorer social functioning, greater suicidal ideation and a higher likelihood of prescription of benzodiazepines, as well as poorer treatment response.13,14”
From Acceptance and commitment therapy for older people with treatment-resistant generalised anxiety disorder: The FACTOID feasibility study (2021) · cites this paper as [13]
In the citing paper
“For example, comorbid anxiety and depression is associated with more severe somatic symptoms, poorer social functioning, greater suicidal ideation and a higher likelihood of prescription of benzodiazepines, as well as poorer treatment response.13,14”
From Acceptance and commitment therapy for older people with treatment-resistant generalised anxiety disorder: The FACTOID feasibility study (2021) · cites this paper as [13]
In the citing paper
“Several factors are associated with treatment-resistant anxiety, including comorbid physical and mental health conditions, noncompliance and environmental stressors.13”
From Acceptance and commitment therapy for older people with treatment-resistant generalised anxiety disorder: The FACTOID feasibility study (2021) · cites this paper as [13]
In the citing paper
“Physical and mental health comorbidity (e.g.depression, other anxiety disorders, personality disorders, mild cognitive deficits, physical ill-health, pain) is common in TR-GAD and is associated with poor treatment response.13”
From Acceptance and commitment therapy for older people with treatment-resistant generalised anxiety disorder: The FACTOID feasibility study (2021) · cites this paper as [13]
In the citing paper
“Although treatment for anxiety disorders produces moderate QOL improvements, not all individuals respond to these front-line interventions, and those who are treatment refractory exhibit particularly low QOL and increased rates of suicide [85].”
From Correlates of Quality of Life in Anxiety Disorders: Review of Recent Research (2021) · cites this paper as [85]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Kessler, R. C. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950010008002 · Cited by 12,370
Kessler, R. C., Chiu, W. T., Demler, O., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.617 · Cited by 12,052
Prevalence and Treatment of Mental Disorders, 1990 to 2003
Kessler, R. C., Demler, O., Frank, R. G., Olfson, M., Pincus, H. A., Walters, E. E., Wang, P., Wells, K. B., & Zaslavsky, A. M. (2005) · New England Journal of Medicine · doi:10.1056/nejmsa043266 · Cited by 1,910
The Emotional Brain, Fear, and the Amygdala
LeDoux, J. (2003) · Cellular and Molecular Neurobiology · doi:10.1023/a:1025048802629 · Cited by 1,818
Neuroanatomical Hypothesis of Panic Disorder, Revised
Gorman, J. M., Kent, J. M., Sullivan, G. M., & Coplan, J. D. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.4.493 · Cited by 1,004
Barlow, D. H., Gorman, J. M., Shear, M. K., & Woods, S. W. (2000) · JAMA · doi:10.1001/jama.283.19.2529 · Cited by 953
Bandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., WFSBP TASK FORCE ON TREATMENT GUIDE, Bandelow, B., Zohar, J., Hollander, E., Kasper, S., et al. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802465807 · Cited by 854
Neuroimaging and frontal–subcortical circuitry in obsessive–compulsive disorder
Saxena, S., Brody, A. L., Schwartz, J. M., & Baxter, L. R. (1998) · British Journal of Psychiatry · doi:10.1192/s0007125000297870 · Cited by 831
Long-term treatment with vagus nerve stimulation in patients with refractory epilepsy
Morris, G. L., Mueller, W. M., & The Vagus Nerve Stimulation Study Group E–E (1999) · Neurology · doi:10.1212/wnl.53.8.1731 · Cited by 724
Groves, D. A., & Brown, V. J. (2005) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2005.01.004 · Cited by 675
Acute and Long-Term Effects of Subthalamic Nucleus Stimulation in Parkinson's Disease
Benabid, A. L., Pollak, P., Gross, C., Hoffmann, D., Benazzouz, A., Gao, D. M., Laurent, A., Gentil, M., & Perret, J. (1994) · Stereotactic and Functional Neurosurgery · doi:10.1159/000098600 · Cited by 532
Deep brain stimulation for refractory obsessive-compulsive disorder
Abelson, J. L., Curtis, G. C., Sagher, O., Albucher, R. C., Harrigan, M., Taylor, S. F., Martis, B., & Giordani, B. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.11.042 · Cited by 522
(2002) · PubMed · Cited by 518
(1998) · PubMed · Cited by 460
The social costs of anxiety disorders
Leon, A. C., Portera, L., & Weissman, M. M. (1995) · British Journal of Psychiatry · doi:10.1192/s0007125000293355 · Cited by 335
Mantovani, A., Lisanby, S. H., Pieraccini, F., Ulivelli, M., Castrogiovanni, P., & Rossi, S. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145705005729 · Cited by 334
(2001) · PubMed · Cited by 332
Lauria-Horner, B. A., & Pohl, R. B. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.12.4.663 · Cited by 327
Andrews, A. M., Gerhardt, G. A., Daws, L. C., Shoaib, M., Mason, B. J., Heyser, C. J., De Lecea, L., Balster, R. L., Walsh, S., Dahmen, M. M., et al. (2010) · Encyclopedia of Psychopharmacology · doi:10.1007/978-3-540-68706-1_4410 · Cited by 322
Treatment outcomes for primary care patients with major depression and lifetime anxiety disorders.
(1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.10.1293 · Cited by 312
(1996) · PubMed · Cited by 310
Neurosurgery for intractable obsessive-compulsive disorder and depression: critical issues
Greenberg, B. D., Price, L. H., Rauch, S. L., Friehs, G., Noren, G., Malone, D., Carpenter, L. L., Rezai, A. R., & Rasmussen, S. A. (2003) · Neurosurgery Clinics of North America · doi:10.1016/s1042-3680(03)00005-6 · Cited by 300
Altered cortical excitability in obsessive–compulsive disorder
Greenberg, B. D., Ziemann, U., Corá-Locatelli, G., Harmon, A., Murphy, D. L., Keel, J. C., & Wassermann, E. M. (2000) · Neurology · doi:10.1212/wnl.54.1.142 · Cited by 285
(1993) · American Journal of Psychiatry · doi:10.1176/ajp.150.10.1485 · Cited by 263
Obsessive-Compulsive Hoarding: Symptom Severity and Response to Multimodal Treatment
Saxena, S., Maidment, K. M., Vapnik, T., Golden, G., Rishwain, T., Rosen, R. M., Tarlow, G., & Bystritsky, A. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0105 · Cited by 238
Self-citationAlonso, P., Pujol, J., Cardoner, N., Benlloch, L., Deus, J., Menchón, J. M., Capdevila, A., & Vallejo, J. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.7.1143 · Cited by 234
Meditation therapy for anxiety disorders
Krisanaprakornkit, T., Sriraj, W., Piyavhatkul, N., & Laopaiboon, M. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004998.pub2 · Cited by 230
Subthreshold Psychiatric Symptoms in a Primary Care Group Practice
Olfson, M. (1996) · Archives of General Psychiatry · doi:10.1001/archpsyc.1996.01830100026004 · Cited by 228
Lochner, C., Mogotsi, M., du Toit, P. L., Kaminer, D., Niehaus, D. J., & Stein, D. J. (2003) · Psychopathology · doi:10.1159/000073451 · Cited by 221
Multivariate Meta-Analysis of Controlled Drug Studies for Obsessive-Compulsive Disorder
Ackerman, D. L., & Greenland, S. (2002) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200206000-00012 · Cited by 202
Cognitive Therapy for Obsessive-Compulsive Disorder: A Guide for Professionals
Wilhelm, S., & Steketee, G. S. (2006) · Cited by 186
Klein, E. (2002) · PubMed · Cited by 182
Rauch, S. L. (2003) · Neurosurgery Clinics of North America · doi:10.1016/s1042-3680(02)00114-6 · Cited by 180
EPIDEMIOLOGY, PATTERNS OF COMORBIDITY, AND ASSOCIATED DISABILITIES OF SOCIAL PHOBIA
Wïttchen, H., & Fehm, L. (2001) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(05)70254-9 · Cited by 176
Neuroimaging Studies of Obsessive Compulsive Disorder
Baxter, L. R. (1992) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(18)30215-6 · Cited by 174
Bandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., & WFSBP Task Force on Treatment Guide (2002) · The World Journal of Biological Psychiatry · doi:10.3109/15622970209150621 · Cited by 167
Advances in the Psychosocial Treatment of Anxiety Disorders: Implications for National Health Care
Barlow, D. H., & Lehman, C. L. (1996) · Archives of General Psychiatry · doi:10.1001/archpsyc.1996.01830080079013 · Cited by 160
Transcranial magnetic stimulation for treating depression
Martín, J. L. R., Barbanoj, M. J., Schlaepfer, T. E., Clos, S., Pérez, V., Kulisevsky, J., & Gironell, A. (2002) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003493 · Cited by 158
Roy-Byrne, P. P., Katon, W., Cowley, D. S., & Russo, J. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.9.869 · Cited by 158
Cosgrove, G. R., & Rauch, S. L. (2003) · Neurosurgery Clinics of North America · doi:10.1016/s1042-3680(02)00115-8 · Cited by 155
How Psychiatrists Can Build New Therapies for Impotence
Stahl, S. M. (1998) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v59n0201 · Cited by 154
Treatment of depressive and obsessive‐compulsive symptoms in OCD by imipramine and behaviour therapy
Foa, E. B., Kozak, M. J., Steketee, G. S., & McCarthy, P. R. (1992) · British Journal of Clinical Psychology · doi:10.1111/j.2044-8260.1992.tb00995.x · Cited by 150
Cognitive schemas and core beliefs in psychological problems: A scientist-practitioner guide.
(2007) · American Psychological Association eBooks · doi:10.1037/11561-000 · Cited by 148
Bystritsky, A., Liberman, R. P., Hwang, S., Wallace, C. J., Vapnik, T., Maindment, K., & Saxena, S. (2001) · Depression and Anxiety · doi:10.1002/da.1069 · Cited by 146
Self-citationAdvances in neurostimulation for movement disorders
Gross, R. E., & Lozano, A. M. (2000) · Neurological Research · doi:10.1080/01616412.2000.11740667 · Cited by 144
Refractory obsessive-compulsive disorder: state-of-the-art treatment.
Hollander, E., Bienstock, C. A., Koran, L. M., Pallanti, S., Marazziti, D., Rasmussen, S. A., Ravizza, L., Benkelfat, C., Saxena, S., Greenberg, B. D., et al. (2002) · PubMed · Cited by 144
Patient perspectives on once-weekly fluoxetine.
Judge, R. (2001) · PubMed · Cited by 144
New vistas in neuropeptide research in neuropsychiatry: focus on corticotropin-releasing factor.
Nemeroff, C. B. (1992) · PubMed · Cited by 133
Jc, B., Davidson, J. R. T., Lecrubier, Y., Nutt, D. J., Borkovec, T. D., Rickels, K., Stein, D. J., & Wittchen, H.-U. (2001) · Max Planck Institute for Plasma Physics · Cited by 133
Double-Blind Treatment With Oral Morphine in Treatment-Resistant Obsessive-Compulsive Disorder
Koran, L. M., Aboujaoude, E. N., Bullock, K. D., Franz, B., Gamel, N. N., & Elliott, M. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0312 · Cited by 132
New standard of depression treatment: remission and full recovery.
Bakish, D. (2001) · PubMed · Cited by 120
Pallanti, S., Quercioli, L., & Bruscoli, M. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n1015 · Cited by 118
Nuttin, B. J., Gabriels, L., Kuyck, K. V., & Cosyns, P. (2003) · Neurosurgery Clinics of North America · doi:10.1016/s1042-3680(02)00117-1 · Cited by 104
Transcranial magnetic stimulation for the treatment of obsessive-compulsive disorder
Rodriguez-Martin, J. L., Barbanoj, J. M., Pérez, V, & Sacristan, M. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003387 · Cited by 103
Pallanti, S., Hollander, E., & Goodman, W. K. (2004) · PubMed · Cited by 98
Prevalence and 12-month outcome of threshold and subthreshold mental disorders in primary care
Pini, S., Perkonnig, A., Tansella, M., Wïttchen, H., & Psich, D. (1999) · Journal of Affective Disorders · doi:10.1016/s0165-0327(99)00141-x · Cited by 98
Obsessive-compulsive disorder: diagnosis and treatment.
Goodman, W. K. (1999) · PubMed · Cited by 93
Bystritsky, A., Saxena, S., Maidment, K., Vapnik, T., Tarlow, G., & Rosen, R. (1999) · Psychiatric Services · doi:10.1176/ps.50.3.412 · Cited by 93
Self-citationPossible role of neuropeptides in obsessive compulsive disorder
McDougle, C. J., Barr, L. C., Goodman, W. K., & Price, L. H. (1999) · Psychoneuroendocrinology · doi:10.1016/s0306-4530(98)00046-8 · Cited by 92
Panic disorder: epidemiology, diagnosis, and treatment in primary care.
Katon, W. J. (1986) · PubMed · Cited by 89
The evidence-based pharmacological treatment of social anxiety disorder
Blanco, C., Raza, M. S., Schneier, F. R., & Liebowitz, M. R. (2003) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145703003791 · Cited by 79
A Review of the Usefulness of the Standard EEG in Psychiatry
Hughes, J. R. (1996) · Clinical Electroencephalography · doi:10.1177/155005949602700106 · Cited by 78
Handbook of behavior therapy and psychological science: An integrative approach
Galassi, J. P. (1992) · Journal of Behavior Therapy and Experimental Psychiatry · doi:10.1016/0005-7916(92)90012-8 · Cited by 74
Emotion-Focused Psychotherapy for Patients With Panic Disorder
Shear, M. K., Houck, P. R., Greeno, C. G., & Masters, S. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.12.1993 · Cited by 68
Is Interpersonal Psychotherapy Superior to Supportive Psychotherapy?
BROWN, W. A. (1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.11.1509-a · Cited by 63
The Longitudinal Course and Outcome of Panic Disorder
Pollack, M. H., & Smoller, J. W. (1995) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(18)30023-6 · Cited by 63
Craske, M. G., Edlund, M. J., Sullivan, G., Roy-Byrne, P., Sherbourne, C., Bystritsky, A., & Stein, M. B. (2005) · Psychiatric Services · doi:10.1176/appi.ps.56.8.988 · Cited by 60
Self-citationDeterminants of Pharmacologic Treatment Failure in Panic Disorder
Cowley, D. S., Ha, E. H., & Roy-Byrne, P. P. (1997) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v58n1208 · Cited by 59
Use of Herbal Medicine in Primary Care Patients With Mood and Anxiety Disorders
Roy‐Byrne, P., Bystritsky, A., Russo, J. E., Craske, M. G., Sherbourne, C. D., & Stein, M. B. (2005) · Psychosomatics · doi:10.1176/appi.psy.46.2.117 · Cited by 58
Self-citationAn update on obsessive-compulsive disorder
Jenike, M. A. (2001) · Bulletin of the Menninger Clinic · doi:10.1521/bumc.65.1.4.18714 · Cited by 54
Treating panic disorder in primary care: a collaborative care intervention
Craske, M. G., Roy‐Byrne, P., Stein, M. B., Sherbourne, C. D., Bystritsky, A., Katon, W. J., & Sullivan, G. (2002) · General Hospital Psychiatry · doi:10.1016/s0163-8343(02)00174-3 · Cited by 52
Self-citationCuffel, B. J., Azocar, F., Tomlin, M., Greenfield, S. F., Busch, A. B., & Croghan, T. W. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0406 · Cited by 49
Pharmacotherapy of Panic Disorder: Proposed Guidelines for the Family Physician
Roy-Byrne, P., Stein, M., Bystrisky, A., & Katon, W. (1998) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.11.4.282 · Cited by 44
Pollack, M. H., Meoni, P., Otto, M. W., & Hackett, D. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000084025.22282.84 · Cited by 38
CRASKE, M. G., GOLINELLI, D., STEIN, M. B., ROY-BYRNE, P., BYSTRITSKY, A., & SHERBOURNE, C. (2005) · Psychological Medicine · doi:10.1017/s003329170500557x · Cited by 36
Self-citationLithium Salts in AIDS and AIDS-Related Dementia
Harvey, B. H., PhD, Meyer, C. L., Manji, H. K., Gallicchio, V. S., PhD, Manji, A. H. K., Frcpc, & FRCPC (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4228 · Cited by 30
Predictors of treatment response in patients with posttraumatic stress disorder
Connor, K. M., Hidalgo, R. B., Crockett, B. A., Malik, M. L., Katz, R. J., & Davidson, J. R. T. (2001) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(00)00163-9 · Cited by 24
Beale, Kellner, C. H., Pritchett, J. T., & Cm, B. (1995) · PubMed · Cited by 22
Cognitive-Behavioral Therapy for Social Anxiety Disorder: Supporting Evidence and Future Directions
Hambrick, J. P., Weeks, J. W., Harb, G. C., & Heimberg, R. G. (2003) · CNS Spectrums · doi:10.1017/s1092852900018630 · Cited by 20
Ruiz (2000) · doi:10.1097/00131746-200005000-00002 · Cited by 14
Sookman, D., & Pinard, G. (2007) · American Psychological Association eBooks · doi:10.1037/11561-005 · Cited by 11
Nickel, C., Tritt, K., Kettler, C., Lahmann, C., Loew, T. H., Rother, W. K., & Nickel, M. (2005) · Wiener klinische Wochenschrift · doi:10.1007/s00508-005-0334-y · Cited by 10
Predictors and outcomes in people told that they have panic attacks
Katerndahl, D. A. (2003) · Depression and Anxiety · doi:10.1002/da.10086 · Cited by 9
Kessler, R. C., & Wïttchen, H. (2000) · Acta Psychiatrica Scandinavica · doi:10.1111/j.0065-1591.2000.acp29-01.x · Cited by 8
Rc, K., & Wïttchen, H. (2000) · PubMed · Cited by 7
Diagnosis and Treatment of Anxiety
Bystritsky, A. (2004) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/foc.2.3.333 · Cited by 4
Self-citation
Research works printed but not linked: 5
- Nemeroff CB . Remission: today's target in the treatment of mood and anxiety disorders. Psychopharmacol Bull 2002; 36: 5.
- Pollack MH, Meoni P, Otto MW, Simon N, Hackett D . Predictors of outcome following venlafaxine extended-release treatment of DSM-IV generalized anxiety disorder: a pooled analysis of short- and long term studies. J Clin Psychopharmacol 2003; 23: 250–259.
- Barlow DH, Gorman JM, Shear MK, Woods SW . Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trial. JAMA 2000; 283: 2529–2536. · DOI · Paper page
- Beale MD, Kellner CH, Pritchett JT, Burns CM . ECT for OCD. J Clin Psychiatry 1995; 56: 81–82.
- Rush AJ, Marangell LB, Sackeim HA, George MS, Brannan SK, Davis SM et al. Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial. Biol Psychiatry 2005; 58: 347–354. · DOI · Paper page
Cited by
Frontal midline theta reflects anxiety and cognitive control: Meta-analytic evidence
Cavanagh, J. F., & Shackman, A. J. (2015) · Journal of Physiology-Paris · doi:10.1016/j.jphysparis.2014.04.003 · Cited by 623
“These psychiatric disorders are highly prevalent, debilitating, and challenging to treat (Bystritsky, 2006; Kessler et al., 2012), underscoring the importance of a deeper understanding of the neural systems that confer liability to dispositional anxiety.”
The neurobiology of depression and antidepressant action
Willner, P., Scheel-Krüger, J., & Belzung, C. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2012.12.007 · Cited by 519
Activation of β-catenin by carcinogenic Helicobacter pylori
Franco, A. T., Israel, D. A., Washington, M. K., Krishna, U., Fox, J. G., Rogers, A. B., Neish, A. S., Collier-Hyams, L., Perez-Perez, G. I., Hatakeyama, M., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504927102 · Cited by 479
Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options
Garakani, A., Murrough, J. W., Freire, R. C., Thom, R. P., Larkin, K., Buono, F. D., & Iosifescu, D. V. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.595584 · Cited by 440
“The literature, however, indicates that only 60–85% of patients with anxiety disorders respond (experience at least a 50% improvement) to current biological and psychological treatments (6).”
BackgroundCandidate biomarkers in psychiatric disorders: state of the field
Abi‐Dargham, A., Moeller, S. J., Ali, F., DeLorenzo, C., Domschke, K., Horga, G., Jutla, A., Kotov, R., Paulus, M. P., Rubio, J. M., et al. (2023) · World Psychiatry · doi:10.1002/wps.21078 · Cited by 372
Metadata
- Authors
- Bystritsky, A.
- Affiliations
- University of California, Los Angeles (US)
- Corresponding author
- Bystritsky, A
- ORCID
- Bystritsky, A
- Venue
- Molecular Psychiatry
- Published
- 2006-07-18
- Volume
- 11
- Issue
- 9
- Pages
- 805-814
- ISSN
- 1359-4184 (ISSN-L)
- 1476-5578
- OpenAlex
- W2004241099
- Cited by
- 289
- References
- 88
- Citations by year
- 2026: 14 · 2025: 24 · 2024: 31 · 2023: 23 · 2022: 23 · 2021: 25 · 2020: 10 · 2019: 22 · 2018: 17 · 2017: 18 · 2016: 22 · 2015: 10 · 2014: 10 · 2013: 8 · 2012: 4
- FWCI
- 0.54
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Molecular Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Clinical Psychology › Psychological Treatments and Disorders
- Keywords
- anxiety disorders, treatment resistance, serotonin reuptake inhibitors, cognitive behavioral therapy, residual symptoms, suicide attempts, quality of life, chronic anxiety, biological factors, social factors
- MeSH terms
- Anxiety Disorders, Humans, United States, Treatment Outcome, Selective Serotonin Reuptake Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.